CN118557602A - 线粒体及富含血小板纤维蛋白用于抗发炎及/或增加胶原蛋白含量的用途 - Google Patents

线粒体及富含血小板纤维蛋白用于抗发炎及/或增加胶原蛋白含量的用途 Download PDF

Info

Publication number
CN118557602A
CN118557602A CN202410555655.9A CN202410555655A CN118557602A CN 118557602 A CN118557602 A CN 118557602A CN 202410555655 A CN202410555655 A CN 202410555655A CN 118557602 A CN118557602 A CN 118557602A
Authority
CN
China
Prior art keywords
mitochondria
composition
collagen content
treating
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410555655.9A
Other languages
English (en)
Chinese (zh)
Inventor
郑汉中
许智凯
曾惠卿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Chung Hsing University
Original Assignee
National Chung Hsing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Chung Hsing University filed Critical National Chung Hsing University
Publication of CN118557602A publication Critical patent/CN118557602A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CN202410555655.9A 2020-03-20 2021-03-19 线粒体及富含血小板纤维蛋白用于抗发炎及/或增加胶原蛋白含量的用途 Pending CN118557602A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062992546P 2020-03-20 2020-03-20
US62/992,546 2020-03-20
CN202180014788.XA CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
PCT/CN2021/081685 WO2021185340A1 (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180014788.XA Division CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途

Publications (1)

Publication Number Publication Date
CN118557602A true CN118557602A (zh) 2024-08-30

Family

ID=77768010

Family Applications (16)

Application Number Title Priority Date Filing Date
CN202410555655.9A Pending CN118557602A (zh) 2020-03-20 2021-03-19 线粒体及富含血小板纤维蛋白用于抗发炎及/或增加胶原蛋白含量的用途
CN202180014670.7A Active CN115135328B (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202180014788.XA Active CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
CN202411951276.8A Pending CN119876009A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202311570784.7A Pending CN117357559A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410329249.0A Pending CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途
CN202410555664.8A Pending CN118557604A (zh) 2020-03-20 2021-03-19 线粒体用于作为促进组织再生或纤维母细胞迁移的组合物的用途
CN202180022924.XA Pending CN115335065A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202410329264.5A Pending CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202311621466.9A Pending CN117379458A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410555661.4A Pending CN118557603A (zh) 2020-03-20 2021-03-19 含有线粒体的组合物
CN202180014777.1A Active CN115103683B (zh) 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途
CN202180022422.7A Active CN115297872B (zh) 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途
CN202180022370.3A Pending CN115315248A (zh) 2020-03-20 2021-03-22 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途
CN202410414725.9A Pending CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物
CN202410414731.4A Pending CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物

Family Applications After (15)

Application Number Title Priority Date Filing Date
CN202180014670.7A Active CN115135328B (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202180014788.XA Active CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
CN202411951276.8A Pending CN119876009A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202311570784.7A Pending CN117357559A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410329249.0A Pending CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途
CN202410555664.8A Pending CN118557604A (zh) 2020-03-20 2021-03-19 线粒体用于作为促进组织再生或纤维母细胞迁移的组合物的用途
CN202180022924.XA Pending CN115335065A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202410329264.5A Pending CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202311621466.9A Pending CN117379458A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410555661.4A Pending CN118557603A (zh) 2020-03-20 2021-03-19 含有线粒体的组合物
CN202180014777.1A Active CN115103683B (zh) 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途
CN202180022422.7A Active CN115297872B (zh) 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途
CN202180022370.3A Pending CN115315248A (zh) 2020-03-20 2021-03-22 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途
CN202410414725.9A Pending CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物
CN202410414731.4A Pending CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物

Country Status (6)

Country Link
US (6) US20230042445A1 (https=)
EP (2) EP4122474A4 (https=)
JP (2) JP7563782B2 (https=)
CN (16) CN118557602A (https=)
TW (12) TWI789724B (https=)
WO (6) WO2021185364A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
US20250186498A1 (en) * 2022-05-16 2025-06-12 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition for hearing loss mitigation and use thereof
CN116478920B (zh) * 2023-05-05 2025-03-25 重庆理工大学 一种离体线粒体的体外储存方法
CN117180312A (zh) * 2023-10-09 2023-12-08 上海市第六人民医院 iMSCs线粒体在制备治疗骨缺损的药物中的应用
CN117883479A (zh) * 2023-11-02 2024-04-16 上海市第六人民医院 人源线粒体在制备治疗跟腱损伤的药物中的应用
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202298B1 (en) * 1984-11-29 1992-07-15 Regents Of The University Of Minnesota Wound healing agents
US6100068A (en) * 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US5834418A (en) * 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
BRPI0507349A (pt) * 2004-02-02 2007-04-17 Nestec Sa genes associados á osteoartrite canina e processos e composições relacionados
TW200817019A (en) * 2006-07-10 2008-04-16 Univ Columbia De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US8734854B2 (en) * 2009-07-09 2014-05-27 Orogen Biosciences Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2741757B1 (en) * 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
EP2591812A1 (en) * 2011-11-14 2013-05-15 University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
US20140024677A1 (en) * 2012-04-09 2014-01-23 Musc Foundation For Research Development Methods for inducing mitochondrial biogenesis
US10702556B2 (en) * 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
AU2013326861A1 (en) * 2012-10-04 2015-04-23 Genesys Research Institute Platelet compositions and uses thereof
CN105163750B (zh) * 2013-02-07 2022-07-15 李震义 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途
US20140271589A1 (en) * 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
ES2883580T3 (es) * 2013-03-21 2021-12-09 Collplant Ltd Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción
US20150064715A1 (en) * 2013-08-28 2015-03-05 Musc Foundation For Research Development Urinary biomarkers of renal and mitochondrial dysfunction
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
TWI672147B (zh) * 2014-09-10 2019-09-21 台灣粒線體應用技術股份有限公司 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法
JP6441472B2 (ja) * 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
CN105520891B (zh) * 2014-09-30 2019-05-21 台湾粒线体应用技术股份有限公司 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN107249600A (zh) * 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
WO2016114781A1 (en) * 2015-01-15 2016-07-21 Boss William K Jr Repair and rejuvenation of tissues using platelet-rich plasma
CN104546915B (zh) * 2015-02-16 2018-12-11 天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物的制备方法
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
CA2987271A1 (en) * 2015-05-22 2016-12-01 President And Fellows Of Harvard College Methods, systems, and compositions for determining blood clot formation, and uses thereof
CN105030647B (zh) * 2015-09-14 2018-04-24 广州赛莱拉干细胞科技股份有限公司 一种减少皱纹的制剂及其制备方法
US20180303970A1 (en) * 2015-11-02 2018-10-25 VeriGraft AB Compositions and methods for healing wounds
US11903974B2 (en) * 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
SI4272834T1 (sl) * 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
TWI637748B (zh) * 2016-07-12 2018-10-11 中山醫學大學 蓮蓬萃取物用於治療及／或預防腎臟病變之用途
CN106190963A (zh) * 2016-07-13 2016-12-07 浙江大学 一种采用线粒体移植促进损伤神经元存活的方法
EP3549589A4 (en) * 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
CN106822183B (zh) * 2016-12-26 2020-04-14 中山光禾医疗科技有限公司 一种光敏富血小板血浆凝胶及其制备方法和用途
US20200023005A1 (en) * 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
US20200268940A1 (en) * 2017-05-15 2020-08-27 Richard J. Miron Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules
EP3630134B8 (en) * 2017-06-01 2022-01-19 The United States of America as represented by The Secretary Department of Health and Human Services Formation of stable cartilage
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
CN107625969A (zh) * 2017-10-18 2018-01-26 南京市儿童医院 MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途
WO2019083201A2 (ko) * 2017-10-24 2019-05-02 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도
KR20190052266A (ko) * 2017-11-08 2019-05-16 원광대학교산학협력단 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물
KR102275822B1 (ko) * 2018-02-02 2021-07-12 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程
WO2019183042A1 (en) * 2018-03-20 2019-09-26 Unity Biotechnology, Inc. Autologous mitochondrial extraction and expansion
US12329781B2 (en) * 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
CN112601532A (zh) * 2018-07-22 2021-04-02 米诺维亚疗法有限公司 使用富集有功能性线粒体的干细胞的线粒体增强疗法
US12268714B2 (en) * 2018-09-14 2025-04-08 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
KR102128003B1 (ko) * 2018-10-31 2020-06-29 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물
CN110055216A (zh) * 2019-05-09 2019-07-26 张秀明 一种改善间质干细胞生物学功能的方法
CN110638833A (zh) * 2019-11-15 2020-01-03 西安圣德生物科技有限公司 促进毛发生长的组合物及其使用方法
CN110812480B (zh) * 2019-11-28 2021-04-02 中国科学院昆明动物研究所 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途

Also Published As

Publication number Publication date
CN118252850A (zh) 2024-06-28
US20230023438A1 (en) 2023-01-26
US20230137870A1 (en) 2023-05-04
CN115103683A (zh) 2022-09-23
TW202308668A (zh) 2023-03-01
TWI789723B (zh) 2023-01-11
WO2021185340A1 (zh) 2021-09-23
WO2021185364A1 (zh) 2021-09-23
EP4122474A1 (en) 2023-01-25
CN117379458A (zh) 2024-01-12
JP2023518083A (ja) 2023-04-27
US20230023218A1 (en) 2023-01-26
CN115297872B (zh) 2024-03-29
CN115315248A (zh) 2022-11-08
JP7563782B2 (ja) 2024-10-08
TWI849298B (zh) 2024-07-21
TW202135779A (zh) 2021-10-01
CN115335065A (zh) 2022-11-11
WO2021185376A1 (zh) 2021-09-23
CN115315265A (zh) 2022-11-08
CN115315265B (zh) 2024-05-31
TW202504624A (zh) 2025-02-01
CN118319950A (zh) 2024-07-12
TW202135837A (zh) 2021-10-01
CN115135328A (zh) 2022-09-30
TW202135838A (zh) 2021-10-01
EP4122444A1 (en) 2023-01-25
TWI908184B (zh) 2025-12-11
JP2024133717A (ja) 2024-10-02
TW202442248A (zh) 2024-11-01
TWI796653B (zh) 2023-03-21
US20230165899A1 (en) 2023-06-01
WO2021185341A1 (zh) 2021-09-23
TWI827321B (zh) 2023-12-21
CN118236473A (zh) 2024-06-25
TW202438034A (zh) 2024-10-01
TW202135836A (zh) 2021-10-01
WO2021185377A1 (zh) 2021-09-23
CN118557604A (zh) 2024-08-30
US20230042445A1 (en) 2023-02-09
TW202404618A (zh) 2024-02-01
CN115103683B (zh) 2024-04-09
CN118557603A (zh) 2024-08-30
WO2021185342A1 (zh) 2021-09-23
EP4122444A4 (en) 2024-04-17
TWI789724B (zh) 2023-01-11
TWI860566B (zh) 2024-11-01
TW202135839A (zh) 2021-10-01
TWI787761B (zh) 2022-12-21
TW202200781A (zh) 2022-01-01
CN115135328B (zh) 2024-01-02
CN115297872A (zh) 2022-11-04
TWI787763B (zh) 2022-12-21
TWI857807B (zh) 2024-10-01
US20230016499A1 (en) 2023-01-19
CN118319951A (zh) 2024-07-12
JP7736347B2 (ja) 2025-09-09
TWI853788B (zh) 2024-08-21
EP4122474A4 (en) 2024-05-01
CN117357559A (zh) 2024-01-09
CN119876009A (zh) 2025-04-25
TW202306576A (zh) 2023-02-16

Similar Documents

Publication Publication Date Title
CN115315265B (zh) 线粒体用于促进伤口修复及/或伤口愈合的用途
US20230405180A1 (en) Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-undegradable support composition for skin regeneration or wound healing
Yang et al. Recent advances in the use of extracellular vesicles from adipose-derived stem cells for regenerative medical therapeutics
RU2711330C2 (ru) Сывороточная фракция обогащенного тромбоцитами фибрина
WO2008082323A1 (en) Growth stimulating and cell regenerating composition and a method for the production thereof.
US12016884B2 (en) Adipose derived stem cell exosomes and uses thereof
Zhao et al. Platelet-rich plasma (PRP) in the treatment of diabetic foot ulcers and its regulation of autophagy
CN116889619A (zh) 小分子多肽Elabela在糖尿病溃疡创面愈合中的应用
CN112587720A (zh) 一种cgf和脐带间充质干细胞外泌体混合物、制备及应用
Lai et al. Combination of PDGF-BB and adipose-derived stem cells accelerated wound healing through modulating PTEN/AKT pathway
KR101816964B1 (ko) 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
CN116687837B (zh) 一种促进创面愈合的干细胞制剂及其制备方法
CN113846064A (zh) 一种fgf18基因修饰的间充质干细胞及其制备方法和应用
Sultana et al. Efficacy and safety of platelet rich plasma therapy in male androgenetic alopecia
CN111358749B (zh) 一种促进皮肤伤口愈合的组合物及其制备方法
CN116421710A (zh) 一种促进糖尿病宠物皮肤创伤修复的胶原蛋白-干细胞制剂
CN121629008A (zh) 一种基于VPA-Exo载药外泌体的促进皮肤创伤愈合体外评价模型及其构建方法和应用
CN119970776A (zh) miR-184-3p在制备改善糖尿病相关组织损伤修复的药物中的应用
CN121731284A (zh) 熊竹素在制备促进糖足溃疡创面愈合药物中的应用
CN121370715A (zh) 一种用于延缓细胞衰老、维持组织稳态的组合物及其制备方法和应用
RU2785588C2 (ru) Материал стволовых клеток и способ его получения
CN116421627A (zh) 一种纳米脂肪裂解液的制备方法、纳米脂肪裂解液及其应用
CN121534082A (zh) 一种3d低氧间充质干细胞衍生外泌体制剂在制备免疫细胞增殖抑制剂或治疗急性心肌梗死的药物中的应用
CN120037348A (zh) 一种促进糖尿病伤口愈合组合物及其制备方法、应用
CN115887614A (zh) Netrin-1在促进糖尿病皮肤创面修复中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination